Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE)

Trial Profile

Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Tetracosactide (Primary)
  • Indications Post-dural puncture headache
  • Focus Therapeutic Use
  • Acronyms ESYBRECHE
  • Most Recent Events

    • 11 Oct 2016 Planned End Date changed from 1 Jul 2018 to 1 Dec 2018.
    • 11 Oct 2016 Planned primary completion date changed from 1 Jul 2018 to 1 Nov 2018.
    • 08 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top